⚖️ Legal Notice: FECO/RSO contains high-THC cannabis extract and is federally Schedule I in the United States. It is illegal in many jurisdictions worldwide. Verify local laws before proceeding. This page is for educational purposes only.

Full Spectrum Cannabis · Whole-Plant Extract · High THC

FECO: Full Extract Cannabis Oil Research Guide

By

By , HighPeptides Editor

Last updated: March 2026

Full Extract Cannabis Oil (also called RSO) contains 60–90% THC plus the full cannabinoid and terpene profile of whole-plant cannabis. Preclinical research shows multiple anti-tumor mechanisms. No completed Phase III RCTs in humans as of 2026. Federally illegal in the US.

0%
Up to 90% THC
Typical FECO potency range
0+
Known Cannabinoids
In the cannabis plant
0yrs
Research History
Preclinical data since 1975
📋 On this page
  1. What Is FECO?
  2. How Cannabinoids Act on Cancer Cells
  3. FECO vs CBD Oil — Key Differences
  4. What the Science Shows
  5. Risks & Considerations
  6. Where Is FECO Legal?
  7. Tools for Accurate FECO Dosing
  8. Frequently Asked Questions
  9. Explore Further
Overview

What Is FECO?

Full Extract Cannabis Oil is a concentrated whole-plant cannabis extract made using ethanol solvent. Unlike isolates or distillates, FECO retains the complete cannabinoid and terpene profile — which proponents believe creates synergistic "entourage" effects not achievable with isolated compounds.

What It Contains
Full Cannabinoid & Terpene Profile

FECO preserves the complete chemical complexity of cannabis — all major and minor cannabinoids plus terpenes that may be lost in refined extracts.

THC (60–90%) CBD CBN CBG CBC THCA Terpenes Flavonoids
Also Known As
RSO — Rick Simpson Oil

Rick Simpson popularized this extract type after claiming to treat his own skin cancer with it in 2003. His protocol involved high-dose THC oil taken orally over 90 days. FECO is functionally identical to RSO — the names are used interchangeably, though RSO sometimes refers to a specific dark, tar-like oil while FECO can range in consistency.

Extraction
Ethanol-Based Whole Plant

Ethanol is used as the solvent to strip all soluble compounds from the plant material, then evaporated off. This preserves polar and non-polar compounds alike — including chlorophyll, which gives FECO its characteristic dark green/black color. Supercritical CO₂ can also be used but may lose some terpenes.

Context
Joe Tippens Protocol

FECO/RSO gained renewed attention as part of the Joe Tippens Protocol — a combination regimen involving fenbendazole, vitamin E succinate, CBD oil, and FECO, documented after Tippens' widely-publicized stage 4 lung cancer remission. Whether any single component or the combination drove outcomes remains unknown. See also: Fenbendazole Guide.

Mechanisms of Action

How Cannabinoids Act on Cancer Cells

Preclinical research has identified several molecular pathways through which cannabinoids — particularly THC and CBD — may affect tumor cell biology. These are well-characterized in vitro and in animal models; human translation remains an open question.

🔗
CB1 & CB2 Receptor Activation

THC binds to CB1 receptors (primarily CNS) and CB2 receptors (immune cells, peripheral tissues). CB2 receptor activation in tumor cells has been particularly associated with anti-proliferative effects. Receptor engagement initiates downstream signaling cascades including Akt/mTOR pathway inhibition and ceramide accumulation. CB2 agonism may also modulate the tumor microenvironment via immune cell signaling.

🧪
Ceramide Pathway & ER Stress

The ceramide pathway is the most studied molecular mechanism of cannabinoid-induced cancer cell death. CB receptor activation stimulates ceramide synthesis via sphingomyelinase. Ceramide accumulation triggers endoplasmic reticulum (ER) stress, activating the unfolded protein response. This cascade promotes both autophagy (cellular self-digestion) and apoptosis (programmed cell death) in tumor cells, without similar effects in normal cells.

🌿
Entourage Effect

The entourage effect theory holds that minor cannabinoids (CBN, CBG, CBC) and terpenes (myrcene, limonene, β-caryophyllene) potentiate or modulate the effects of THC and CBD synergistically. β-caryophyllene is itself a CB2 agonist. Some terpenes may increase cannabinoid bioavailability by enhancing cell membrane permeability. This is the primary rationale for preferring whole-plant FECO over isolated THC or CBD.

Cannabinoid → Cancer Cell Death Pathway
THC/CBD Binding
CB1 & CB2 Receptors
→
Ceramide Accumulation
Sphingomyelinase activation
→
ER Stress Response
UPR activation
→
Autophagy
Beclin-1 pathway
→
Apoptosis
Caspase cascade

Additionally: anti-angiogenesis (VEGF reduction), inhibition of tumor cell migration, and immune modulation via CB2 on tumor-infiltrating lymphocytes.

Comparison

FECO vs CBD Oil — Key Differences

These products are fundamentally different in composition, legal status, and intended use. Understanding the distinction is critical before researching either.

Property FECO / RSO CBD Oil (Hemp)
THC Content 60–90% THC <0.3% THC (federally legal threshold)
Psychoactive Yes — significantly No
Spectrum Full-spectrum: all cannabinoids + terpenes Varies: full-spectrum, broad-spectrum, or isolate
Source Plant Cannabis (marijuana) — high-THC cultivars Hemp — low-THC industrial cultivars
Federal Legal (US) Illegal — Schedule I Legal (2018 Farm Bill)
Entourage Effect Full profile Partial (no THC)
Dosing Microgram titration required; start at rice-grain dose Standard drops/capsules; wide safety margin
Chemo Side Effect Relief Strong antiemetic, analgesic, appetite stimulant Mild antiemetic; less potent for nausea/pain
Tolerance Develops with chronic use Minimal tolerance reported
Primary Cancer Research Preclinical animal models; some Phase I/II trials Preclinical; fewer human trials for cancer
Research Evidence

What the Science Shows

Evidence ranges from robust preclinical data to limited human trials. Evidence levels are rated relative to each category's ideal standard.

Preclinical Anti-Tumor Evidence
Velasco et al. 2012 (Nature Reviews Cancer) — Multiple tumor types, multiple mechanisms confirmed in cell & animal models
Strong
THC Lung Adenocarcinoma Inhibition (Mouse)
Munson et al. 1975 — First published study; THC inhibited Lewis lung adenocarcinoma growth in mice
Historical
THC + Temozolomide Synergy (Glioblastoma, Mouse)
Torres et al. 2011 — THC combined with TMZ showed synergistic tumor reduction in GBM xenografts
Preclinical
Nabiximols Phase II GBM Trial (Human)
GW Pharmaceuticals — THC:CBD (Sativex) showed improved 1-year survival vs placebo in recurrent GBM (preliminary)
Phase II Only
Phase III Human RCT Evidence for Cancer
No completed Phase III RCTs have established FECO/cannabinoids as a cancer treatment as of 2026
—
Supportive Care Evidence (Antiemetic, Analgesic)
FDA-approved dronabinol (synthetic THC) for chemo-induced nausea; cannabinoids well-established for symptom management
Strong
The Evidence Gap: There is a significant disconnect between robust preclinical anti-tumor data and confirmed human efficacy. Many compounds that kill cancer cells in dishes or mice fail in human trials due to bioavailability, dosing, tumor microenvironment differences, and other factors. The existing human data (Phase I/II) is preliminary and does not establish FECO as a cancer treatment. Supportive care use (nausea, pain, appetite) has much stronger human evidence.
Safety Profile

Risks & Considerations

FECO contains 60–90% THC. High-dose THC presents significant psychoactive and practical risks that must be understood before use. Drug interactions are particularly relevant for cancer patients on chemotherapy.

⚠️ Primary Risks
  • Severe psychoactive impairment — cognitive, coordination, and judgment effects at high THC doses
  • Anxiety, paranoia, and psychosis risk — particularly in naive users and at high doses
  • CYP3A4 & CYP2C9 enzyme inhibition — affects metabolism of many cancer drugs, blood thinners, and antiretrovirals
  • Cardiovascular effects — transient tachycardia and blood pressure changes
  • Legal risk — federally Schedule I; possession can result in criminal prosecution
⚡ Ongoing Concerns
  • Tolerance development — efficacy may decrease with chronic high-dose use
  • Cannabis Use Disorder — dependence possible with prolonged use
  • Quality control — unregulated products may contain pesticides, solvents, or incorrect potency labeling
  • Drug-drug interactions — always disclose to oncologist if using alongside chemotherapy
  • Memory and cognition — long-term heavy THC use associated with cognitive effects
💊 Drug Interactions (CYP)
  • CYP3A4 substrate drugs: paclitaxel, docetaxel, vincristine, tamoxifen — levels may increase
  • CYP2C9 substrates: warfarin (significant bleeding risk), phenytoin, NSAIDs
  • CNS depressants: alcohol, benzodiazepines — additive sedation
  • Immunosuppressants: cyclosporine — narrow therapeutic window affected
🚫 Absolute Cautions
  • Personal or family history of psychosis or schizophrenia — THC is a known trigger
  • Pregnancy and breastfeeding — associated with adverse fetal outcomes
  • Operating heavy machinery or driving — impaired reaction time and judgment
  • Pediatric use without specialist oversight — significant developmental risk
Legal Status

Legal status is highly jurisdiction-dependent and changes frequently. The information below is general and not legal advice. Always verify current laws in your specific location.

🇺🇸
United States (Federal)
Schedule I
Illegal federally. Legal in 24+ states for adult use; medical only in others. State law does not override federal enforcement risk.
🇨🇦
Canada
Legal
Federally legal since 2018 Cannabis Act. Cannabis extracts legal with purchase limits. Requires licensed retailer.
🇩🇪
Germany
Partial Legal
Cannabis legalized April 2024 for adults (limited personal possession). Medical cannabis available via prescription since 2017.
🌍
Rest of World
Varies
Ranges from full prohibition to decriminalization to medical programs. Netherlands, Uruguay, Thailand have varying degrees of legal access.

Important: Even in US states where cannabis is legal, FECO products from dispensaries may vary widely in cannabinoid ratios and quality. Only purchase from licensed, lab-tested sources. Bringing cannabis across state lines remains a federal crime even between two legal states.

Dosing Equipment

Tools for Accurate FECO Dosing

FECO is a thick, viscous oil that requires precision equipment for accurate dosing. Starting doses are very small (a grain-of-rice amount), so precise measurement tools are essential for safe titration.

💉 Glass Oral Syringes (1mL)

Precise measurement essential for FECO micro-dosing. Glass preferred over plastic for viscous oil and easy cleaning. Graduated in 0.1mL increments for accurate starting doses.

View on Amazon → 💊 Capsule Filling Machine

Fill empty gelatin or HPMC capsules with FECO for tasteless, consistent dosing. Size 0 or 00 capsules work well. Machines with 24- or 100-hole trays allow batch preparation.

View on Amazon → 🩺 Blood Pressure Monitor At-home BP tracking. Critical for any compound that affects cardiovascular load. ⚖️ Body Composition Scale Track weight, body fat %, muscle mass for protocol response monitoring. 🩸 Continuous Glucose Monitor Real-time glucose data for any GLP-1 / metabolic peptide research. 📓 Research Notebook Lab notebook for logging dose, timing, and observed effects.

As an Amazon Associate, HighPeptides earns from qualifying purchases. These are general dosing tools — not cannabis products.

FAQ

Frequently Asked Questions

Common questions about FECO, RSO, and cannabinoid research.

FECO (Full Extract Cannabis Oil) is a whole-plant cannabis extract with high THC content — typically 60–90% — along with CBD, CBN, CBG, and the plant's full terpene profile. It is extracted using ethanol solvent and is psychoactive. CBD oil is derived from hemp, contains less than 0.3% THC by law, and produces no intoxicating effects. FECO is federally Schedule I in the US; CBD oil derived from hemp is federally legal. FECO is also known as RSO (Rick Simpson Oil) and is the oil used in alternative cancer protocols like the Joe Tippens Protocol.
Preclinical research is genuinely compelling. Velasco et al. (2012, Nature Reviews Cancer) documented multiple mechanisms by which cannabinoids inhibit tumor growth in cell lines and animal models — apoptosis induction via ceramide accumulation, autophagy, anti-angiogenesis, and immune modulation. Munson et al. (1975) were the first to show THC inhibiting Lewis lung adenocarcinoma in mice. Torres et al. (2011) showed synergy between THC and temozolomide in glioblastoma mouse models. A preliminary Phase II trial by GW Pharmaceuticals showed improved survival in recurrent GBM with nabiximols. However, as of 2026, no completed Phase III randomized controlled trials have established cannabinoids as a human cancer treatment. The preclinical-to-clinical translation has not been proven.
The entourage effect describes the proposed synergy between cannabinoids, terpenes, and other cannabis compounds — the idea that the whole is greater than the sum of its parts. It's the primary rationale for using full-spectrum FECO over isolated THC or CBD. There is preclinical evidence supporting this: β-caryophyllene (a terpene) is itself a CB2 agonist; some terpenes appear to modulate CB receptor binding; minor cannabinoids like CBG and CBN have independent pharmacological activity. However, robust human clinical trial data specifically comparing full-spectrum extracts to isolates for cancer outcomes does not exist. The entourage effect is scientifically plausible and has preclinical support, but has not been definitively proven in controlled human studies.
FECO is federally Schedule I in the United States because of its high THC content. This means it is illegal under federal law regardless of your state's cannabis laws. It is legal for adult or medical use in many US states, Canada, Germany (since 2024), and several other jurisdictions — but remains illegal in many countries. You cannot legally transport FECO across international borders, across US state lines (even between two legal states), or into federal property. Penalties vary enormously by jurisdiction. Always verify your specific local laws before purchasing, possessing, or using FECO.
The most clinically significant interactions involve CYP enzyme inhibition. THC and CBD inhibit CYP3A4 and CYP2C9, which metabolize a wide range of medications. For cancer patients this is particularly important: paclitaxel, docetaxel, vincristine, and tamoxifen are all CYP3A4 substrates — FECO use could increase their blood levels and toxicity. Warfarin (CYP2C9) interaction can increase bleeding risk significantly. CNS depressants including benzodiazepines and opioids will have additive sedation. Always disclose FECO use to your oncologist or prescribing physician before starting — this is non-negotiable.
FECO is a potent extract and must be titrated carefully. The conventional starting protocol begins with a dose the size of a grain of rice — approximately 5–10mg of THC — taken orally once or twice daily. The dose is increased slowly over 3–5 weeks as tolerance develops. Rick Simpson's original protocol targeted 1 gram of oil per day (500–900mg THC) over 90 days, but this is an extreme dose that causes intense psychoactive effects and is difficult for most people to tolerate. Most users find much lower doses practical. Use glass oral syringes (1mL graduated) to measure precise volumes. Some people fill empty capsules using a capsule filling machine for convenience and taste masking. Working with a cannabis-knowledgeable healthcare provider is strongly recommended.
Joe Tippens was diagnosed with small-cell lung cancer in 2016 and given 3 months to live. He began a self-directed protocol including fenbendazole (an anthelmintic), vitamin E succinate, CBD oil, and FECO. His cancer went into complete remission within months, documented by his oncologist. While his case attracted enormous attention, it remains a single anecdotal case — not a clinical trial. It's impossible to determine which component(s) were responsible for his outcome, whether his diagnosis was correct, or whether spontaneous remission occurred. The Tippens Protocol has driven significant interest in both fenbendazole and cannabinoids for cancer. See our Fenbendazole Research Guide for more.
Related Research

Explore Further

These compounds are frequently used alongside FECO in alternative cancer protocols and complementary research stacks.

🦠
Fenbendazole Research Guide
Anthelmintic with preclinical anti-tumor data. Core compound in the Joe Tippens Protocol alongside FECO.
→
🔵
Methylene Blue Research Guide
Mitochondrial electron carrier with anti-tumor, neuroprotective, and cognitive-enhancing research data.
→
📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.


Get the Guide →
⚠️ Medical & Legal Disclaimer

This page is for educational and informational purposes only. Nothing on this page constitutes medical advice, diagnosis, or treatment recommendations. FECO (Full Extract Cannabis Oil / RSO) contains high-THC cannabis extract and is federally Schedule I in the United States — illegal under federal law. Legal status varies widely by jurisdiction. You are solely responsible for verifying the laws in your location before purchasing, possessing, or using any cannabis product. Always consult a qualified healthcare provider before making any medical decisions, particularly if you are undergoing cancer treatment or taking prescription medications. HighPeptides does not endorse the use of FECO as a cancer treatment. The preclinical evidence summarized here has not been validated in completed Phase III human clinical trials.